Literature DB >> 28606411

Can Parasitic Worms Cure the Modern World's Ills?

Margaret M Harnett1, William Harnett2.   

Abstract

There has been increasing recognition that the alarming surge in allergy and autoimmunity in the industrialised and developing worlds shadows the rapid eradication of pathogens, such as parasitic helminths. Appreciation of this has fuelled an explosion in research investigating the therapeutic potential of these worms. This review considers the current state-of-play with a particular focus on exciting recent advances in the identification of potential novel targets for immunomodulation that can be exploited therapeutically. Furthermore, we contemplate the prospects for designing worm-derived immunotherapies for an ever-widening range of inflammatory diseases, including, for example, obesity, cardiovascular disease, and ageing as well as neurodevelopmental disorders like autism.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28606411     DOI: 10.1016/j.pt.2017.05.007

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  18 in total

Review 1.  Harnessing helminth-driven immunoregulation in the search for novel therapeutic modalities.

Authors:  Stephanie M Ryan; Ramon M Eichenberger; Roland Ruscher; Paul R Giacomin; Alex Loukas
Journal:  PLoS Pathog       Date:  2020-05-14       Impact factor: 6.823

Review 2.  Macrophage Activation and Functions during Helminth Infection: Recent Advances from the Laboratory Mouse.

Authors:  Marion Rolot; Benjamin G Dewals
Journal:  J Immunol Res       Date:  2018-07-02       Impact factor: 4.818

3.  The parasitic worm product ES-62 normalises the gut microbiota bone marrow axis in inflammatory arthritis.

Authors:  James Doonan; Anuradha Tarafdar; Miguel A Pineda; Felicity E Lumb; Jenny Crowe; Aneesah M Khan; Paul A Hoskisson; Margaret M Harnett; William Harnett
Journal:  Nat Commun       Date:  2019-04-05       Impact factor: 14.919

4.  Site-specific glycoproteomic characterization of ES-62: The major secreted product of the parasitic worm Acanthocheilonema viteae.

Authors:  Simon J North; Kwamina Botchway; James Doonan; Felicity E Lumb; Anne Dell; William Harnett; Stuart M Haslam
Journal:  Glycobiology       Date:  2019-07-19       Impact factor: 4.313

5.  Particles from the Echinococcus granulosus Laminated Layer Inhibit CD40 Upregulation in Dendritic Cells by Interfering with Akt Activation.

Authors:  Álvaro Pittini; Yamila E Martínez-Acosta; Cecilia Casaravilla; Paula I Seoane; Dominik Rückerl; Celia Quijano; Judith E Allen; Álvaro Díaz
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

6.  The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageing.

Authors:  Jenny Crowe; Felicity E Lumb; James Doonan; Margaux Broussard; Anuradha Tarafdar; Miguel A Pineda; Carmen Landabaso; Lorna Mulvey; Paul A Hoskisson; Simon A Babayan; Colin Selman; William Harnett; Margaret M Harnett
Journal:  PLoS Pathog       Date:  2020-03-12       Impact factor: 6.823

7.  GAS6 signaling tempers Th17 development in patients with multiple sclerosis and helminth infection.

Authors:  Juan M Ortiz Wilczyñski; Cinthia M Olexen; Andrea E Errasti; Mirta Schattner; Carla V Rothlin; Jorge Correale; Eugenio A Carrera Silva
Journal:  PLoS Pathog       Date:  2020-12-21       Impact factor: 6.823

8.  IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62.

Authors:  Dimity H Ball; Lamyaa Al-Riyami; William Harnett; Margaret M Harnett
Journal:  Sci Rep       Date:  2018-03-14       Impact factor: 4.379

9.  A Role for Epitope Networking in Immunomodulation by Helminths.

Authors:  E Jane Homan; Robert D Bremel
Journal:  Front Immunol       Date:  2018-07-31       Impact factor: 7.561

10.  Schistosoma japonicum peptide SJMHE1 suppresses airway inflammation of allergic asthma in mice.

Authors:  Wenzhe Zhang; Li Li; Yu Zheng; Fei Xue; Mengzhu Yu; Yongbin Ma; Liyang Dong; Zirui Shan; Dingqi Feng; Ting Wang; Xuefeng Wang
Journal:  J Cell Mol Med       Date:  2019-09-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.